Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Location: United States, Maryland, Gaithersburg
Employees: 1001-5000
Founded date: 1998
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Advent Lif... | adventls.c... |
Mentions in press and media 23
| Date | Title | Description |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences. BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 11.11.2025 | PDA Releases Three New Foundational Documents to Advance Aseptic Processing and Sterilizing Filtration Practices | These documents reflect PDA's ongoing dedication to providing the pharmaceutical industry with high-quality, practical resources that promote excellence in sterile product manufacturing. BETHESDA, Md., Nov. 11, 2025 /PRNewswire-PRWeb/ -- Th... |
| 13.10.2025 | China’s MGI Gains After Licensing Gene Sequencing Tech to Swiss Rockets for USD120 Million | (Yicai) Oct. 13 -- MGI Tech’s stock price rose after the Chinese supplier of gene-sequencing gear agreed to license the regional marketing rights for its CoolMPS technology to Swiss Rockets for USD120 million. After jumping by as much as 9 ... |
| 05.08.2025 | Biggest Funding Rounds in Serbia (H1 2025) | Serbia ~ Company: Below, you can find the biggest H1 2025 funding rounds in Serbia, along with key details about the startups. Check the rest of the Central and Eastern Europe H1 2025 mappings here. This article is part of the CEE funding m... |
| 20.03.2025 | Syngene completes US biologics site acquisition, shares trade flat | Syngene International had informed the exchanges late last night that Syngene USA has completed the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSoluti... |
| 14.03.2025 | Swiss Rockets obtains strategic investment | Rocketvax Ltd one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies. One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrat... |
| 10.03.2025 | Syngene acquires first US facility from Emergent Manufacturing | Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has invested around $50 million, including the co... |
| 27.01.2025 | The 2025 PDA Board of Directors: A Diverse Range of Interests and Expertise | The 2025 PDA Board of Directors The officers and directors represent pharmaceutical/biopharmaceutical businesses of all sizes and areas of competency across the United States, Europe and Asia. BETHESDA, Md., Jan. 27, 2025 /PRNewswire-PRWeb/... |
| 06.08.2024 | Back-to-school shopping? Here's one item to add to your cart | Sorry, but your browser does not support the video tag. (BPT) - Do you have a teenager or young adult heading back to school this year? Are you looking for peace of mind that they will stay safe? While picking up school supplies, clothing, ... |
| 11.03.2024 | Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense | - |
Show more